Our research broadens the knowledge of kidney disease.

Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period

Christopher D. Blosser, Gregory Haber, Eric A. Engels

Recipients of kidney transplants have elevated cancer risk compared with the general population. Improvements over time in transplant care and cancer treatment may have affected incidence and outcomes of cancer among recipients of kidney transplant. To evaluate this, we used linked United States transplant and cancer registry data to study 101,014 adult recipients of kidney transplants over three decades (1987-1996, 1997-2006, 2007-2016). Poisson regression was used to assess trends in incidence for cancer overall and seven common cancers. Associations of cancer with risk of death-censored graft failure (DCGF) and death with functioning graft (DWFG) were evaluated with Cox regression. We also estimated absolute risks of DCGF and graft failure following cancer for recipients transplanted in 2007-2016. There was no significant change in the incidence of cancer overall or for six common cancers in recipients across the 1987-2016 period.

Integrating Conservative kidney management Options and advance care Planning Education (COPE) into routine CKD care: A protocol for a pilot randomised controlled trial

Taylor L Stallings, Jennifer S Temel, Tamar A Klaiman, Michael K Paasche-Orlow, Margarita Alegria, Ann O’Hare, Nina O’Connor, Laura M Dember, Scott D Halpern, Nwamaka D Eneanya

Predialysis education for patients with advanced chronic kidney disease (CKD) typically focuses narrowly on haemodialysis and peritoneal dialysis as future treatment options. However, patients who are older or seriously ill may not want to pursue dialysis and/or may not benefit from this treatment. Conservative kidney management, a reasonable alternative treatment, and advance care planning (ACP) are often left out of patient education and shared decision-making. In this study, we will pilot an educational intervention (Conservative Kidney Management Options and Advance Care Planning Education—COPE) to improve knowledge of conservative kidney management and ACP among patients with advanced CKD who are older and/or have poor functional status.

The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network

Jonathan P Troost, Anne Waldo, Noelle E Carlozzi, Shannon Murphy, Frank Modersitzki, Howard Trachtman, Patrick H Nachman, Kimberly J Reidy, David T Selewski, Emily G Herreshoff, Tarak Srivastava, Keisha L Gibson, Vimal K Derebail, Jen Jar Lin, Sangeeta Hingorani, Alessia Fornoni, Fernando C Fervenza, Kamalanathan Sambandam, Ambarish M Athavale, Jeffrey B Kopp, Heather N Reich, Sharon G Adler, Larry A Greenbaum, Katherine M Dell, Gerald Appel, Chia-shi Wang, John Sedor, Frederick J Kaskel, Richard A Lafayette, Meredith A Atkinson, John C Lieske, Christine B Sethna, Matthias Kretzler, Michelle A Hladunewich, Kevin V Lemley, Elizabeth Brown, Kevin E Meyers, Crystal A Gadegbeku, Lawrence B Holzman, Jonathan Ashley Jefferson, Katherine R Tuttle, Pamela Singer, Marie C Hogan, Daniel C Cattran, Laura Barisoni, Debbie S Gipson, the Nephrotic Syndrome Study Network

Understanding the relationship between clinical and patient-reported outcomes (PROs) will help support clinical care and future clinical trial design of novel therapies for focal segmental glomerulosclerosis (FSGS).

Rationale and design of the Kidney Precision Medicine Project

Ian H. de Boer, Charles E .Alpers, Evren U. Azeloglu, Ulysses G. J. Balis, Jonathan M .Barasch, Laura Barisoni, Kristina N. Blank, Andrew S. Bomback, Keith Brown, Pierre C. Dagher, Ashveena L. Dighe, Michael T .Eadon, Tarek M. El-Achkar, Joseph P. Gaut, Nir Hacohen, Yongqun He, Jeffrey B. Hodgi, Sanjay Jain, John A. Kellum, Krzysztof Kiryluk, Richard Knight, Zoltan G. Laszik, Chrysta Lienczewski, Laura H. Mariani, Robyn L. McClelland, Steven Menez, Dennis G. Moledina, Sean D. Mooney, John F. O’Toole, Paul M. Palevsky, Chirag R. Parikh, Emilio D. Poggio, Sylvia E .Rosas, Matthew R. Rosengart, Minnie M. Sarwal, Jennifer A. Schaub, John R. Sedor, Kumar Sharma, Becky Steck, Robert D. Toto, Olga G. Troyanskaya, Katherine R. Tuttle, Miguel A. Vazquez, Sushrut S. Waikar, Kayleen Williams, Francis Perry Wilson, Kun Zhang, Ravi Iyengar, Matthias Kretzler, Jonathan Himmelfarb, for the Kidney Precision Medicine Project including Glenda Roberts, Stuart Shankland, et al.

Chronic kidney disease (CKD) and acute kidney injury (AKI) are common, heterogeneous, and morbid diseases. Mechanistic characterization of CKD and AKI in patients may facilitate a precision-medicine approach to prevention, diagnosis, and treatment. The Kidney Precision Medicine Project aims to ethically and safely obtain kidney biopsies from participants with CKD or AKI, create a reference kidney atlas, and characterize disease subgroups to stratify patients based on molecular features of disease, clinical characteristics, and associated outcomes. An additional aim is to identify critical cells, pathways, and targets for novel therapies and preventive strategies.

Innovating and invigorating the clinical trial infrastructure for glomerular diseases

Laura Barisoni, Jonathan Barratt, Kirk Campbell, Lauren Eva, Barbara S. Gillespie, Debbie Gipson, Tobias Huber, Meg Jardine, Elaine Kamil, Matthias Kretzler, Lauren Lee, Elena Levtchenk, Ali Poyan Mehr, Patrick H. Nachman, Jun Oh, Moin Saleem, Stuart J. Shankland, Kimberly Smith, Irv Smokler, William Smoyer, Josh Tarnoff, Aliza Thompson, Howard Trachtman, Suneel Udani, Marina Vivarelli, Patrick Walker, Melissa West, Brad H. Rovin

The current treatment of glomerular diseases is based largely on expert opinion, and small clinical studies from many years ago. Thankfully, there has been recent intense interest from the pharmaceutical industry in bringing drugs for glomerular diseases to trial, despite past failures. This is due, in part, to research efforts that have increasingly revealed molecular mechanisms of disease, facilitating the development of targeted therapeutics, as well as work undertaken by the larger nephrology community to support the use of surrogate end points, such as proteinuria, as efficacy end points in clinical trials of glomerular disease. Such efforts highlight how effective data sharing can greatly facilitate drug development for rare diseases.

Patient perspectives and involvement in precision medicine research

Katherine R. Tuttle, Jack Bebiak, Keith Brown, Catherine Campbell, Ashveena Dighe, Lynda Hyashi, Nichole Jefferson, Glenda V. Roberts, Christy Stutzke, Richard Knight, for the Kidney Precision Medicine Project, including  Asheveena Dighe, Ian de Boer, Jonathan Himmelfarb, Stuart Shankland

A lack of patient perspectives and involvement in the development of scientific inquiries at the discovery phase has been a major barrier to clinical translation of knowledge that advances patient care. Although patient partners have recently become involved in the clinical phase of nephrology research, they were largely absent in the discovery phase until KPMP. To conduct scientific inquiry guided toward clinically meaningful benefit and build public trust, a major goal of the KPMP from its inception has been inclusion of patients as equal partners for priority setting, study design and conduct, and dissemination of findings.

Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists

Emily J Cox, Radica Z Alicic, Joshua J Neumiller, Katherine R Tuttle

Coincident with the diabetes pandemic, diabetic complications—especially kidney disease and cardiovascular disease—have become large-scale public health problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, a newer class of anti-hyperglycemic therapies, represent a major advance in the treatment of these complications in type 2 diabetes. In addition to effectively treating hyperglycemia, they have a low intrinsic risk of hypoglycemia and promote reductions in blood pressure and body weight. Furthermore, in clinical trials of GLP-1 receptor agonists, the risks of cardiovascular events and new or worsening diabetic kidney disease (DKD) were reduced. As a result, guidelines from major professional organizations now recommend GLP-1 receptor agonists for patients with type 2 diabetes, to reduce the risk of atherosclerotic cardiovascular disease or DKD.

Facility-Level Variation in Dialysis Use and Mortality Among Older Veterans With Incident Kidney Failure

Christina Bradshaw, I-Chun Thomas, Maria E. Montez-Rath, Karl A. Lorenz, Steven M. Asch, John T. Leppert, Virginia Wang, Ann M. O’Hare, Manjula Kurella Tamura

Question - To what extent do dialysis use and mortality vary among older adults with incident kidney failure, and are these variations associated with patient or facility factors? Findings - In this cohort study of 8695 older adults with incident kidney failure, dialysis use varied widely across Veterans Affairs facilities with minimal variation in mortality. Most of the variation was associated with patient characteristics, and no correlation was found between the facility-level rate of dialysis use and mortality. Meaning - Results of this study suggest that there is marked variation in dialysis use practices for older adults across Veterans Affairs facilities.

Social Determinants of Health and Race Disparities in Kidney Transplant

Hannah Wesselman, Christopher Graham Ford, Yuridia Leyva, Xingyuan Li, Chung-Chou H Chang, Mary Amanda Dew, Kellee Kendall, Emilee Croswell, John R Pleis, Yue Harn Ng, Mark L Unruh, Ron Shapiro, Larissa Myaskovsky

Black patients have a higher incidence of kidney failure but lower rate of deceased- and living-donor kidney transplantation compared with White patients, even after taking differences in comorbidities into account. We assessed whether social determinants of health (e.g., demographics, cultural, psychosocial, knowledge factors) could account for race differences in receiving deceased- and living-donor kidney transplantation.

ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention

Johann Morelle, Joanna Stachowska-Pietka, Carl Öberg, Liliana Gadola, Vincenzo La Milia, Zanzhe Yu, Mark Lambie, Rajnish Mehrotra, Javier de Arteaga, Simon Davies 

Sometimes dialysis treatment itself can cause the membrane to change after some years. This means more assessments (evaluations) will be needed to determine whether the person’s peritoneal membrane has changed. Changes in the membrane may require changes to the dialysis prescription. This is needed to achieve the best dialysis outcomes. A key tool for these assessments is the peritoneal equilibration test (PET). It is a simple, standardized and reproducible tool. This tool is used to measure the peritoneal function soon after the start of dialysis. The goal is to understand how well the peritoneal membrane works at the start of dialysis. Later on in treatment, the PET helps to monitor changes in peritoneal function.